News and Press Releases
Trauma-Induced Lung Injury (TILI)
-
Tucson startup looks to human trials for drug to treat lung inflammation
March 2022
-
Aqualung Therapeutic’s ALT-100 Antibody Significantly Reduces ARDS Severity in Both Rat and Porcine (Large Animal) Preclinical Models
Feb 2022
-
Aqualung Therapeutics Corp., an Immunotherapeutics Biotech Company, Closes a $2.5M Convertible Note Raise With a Committed Series A Lead Investor
Jan 2022
-
CEO & Founder of Aqualung Therapeutics Corp., Joe G.N. Garcia MD to Present Corporate Update at the Annual Biotech Showcase
Dec 2021
-
Aqualung Therapeutics Selected to Present at the Phoenix 2021 Venture Madness Competition
August 2021
-
Dr. Garcia Grand Rounds at Houston Methodist
July 2021
-
CEO of Aqualung Therapeutics Corp., Joe G.N. Garcia MD, Named Invited Speaker at the First Annual Acute Respiratory Distress Syndrome Drug Development Summit
June 2021
-
Aqualung Therapeutics Plans A Phase 0 ARDS Trial for eNAMPT Monoclonal Antibody (Alt-100 mAb) Following Type B FDA Meeting
June 2021
-
Healing lungs, improving data, oncology research and more
June 2020
-
AquaLung Therapeutics Corp. Receives NIH Approval to Advance to IND-Enabling Studies Via the STTR Fastrack Phase II Award for Development of A Novel Anti-Inflammatory Therapeutic Antibody for ARDS
May 2020